Indian diagnostic company Premier Medical Corporation (PMC) revealed on Wednesday that it intends to file its COVID-19 Antigen rapid test with the US Food and Drug Administration (FDA) to quickly and conveniently test people in schools, workplaces and doctor's offices.
The company will submit the Sure Status COVID-19 Antigen Card Test to the US FDA for inclusion in the Emergency Use Authorization programme for distribution in the US upon inclusion in the World Health Organization's (WHO) Emergency Use Listing worldwide.
According to the company, the simple and affordable Sure Status COVID-19 Antigen Card test is based on the sample from the nose to determine if it contains viral genetic material, giving results in just about 15 minutes. The specificity is 100% and the sensitivity is 94.5%.
In addition, Premier is the third company in the world and the only Indian-based company to accomplish this feat. The test was entirely developed and manufactured in India. It will be distributed from Somerset, New Jersey by Premier Medical USA Corporation.
Currently, the company is in the process of developing a test for the detection of other variants of COVID-19 based on its patented platform technology and rapid saliva testing, which would be a key part of bringing the virus and its transmission under control.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial